www.Top100Medicine.com - TOP 100 MEDICAL SITES
TOP 100 MEDICAL SITES
 Main  |  Add a Site  |  FREE Content for Your Web-site  |  Bookmark this site  |  Webmaster 
Updated Sat, February 4, 2012.
1.www.galenicom.com2010000
2.www.aerzteblatt.de1310000
3.bmj.bmjjournals.com1060000
4.www.pubmedcentral.nih.gov800000
5.www.medicalnewstoday.com547000
6.www.med1.de522000
7.www.healthcare.gov511000
8.www.emedicine.com481000
9.www.obesityhelp.com393000
10.content.nejm.org371000
11.www.redcross.org343000
12.www.hospital-data.com316000
13.www.medi-learn.de292000
14.www.mdconsult.com285000
15.jama.ama-assn.org282000
16.www.med.univ-rennes1.fr260000
17.www.locateadoc.com250000
18.www.cpsc.gov243000
19.www.nih.gov234000
20.www.med.umich.edu229000
21.www.chestjournal.org226000
22.www.aafp.org215000
23.www.med.nyu.edu204000
24.www.aap.org202000
25.www.aerztlichepraxis.de199000
26.www.medscape.com188000
27.www.aerztestellen.de177000
28.www.gsm.com176000
29.www.efisioterapia.net176000
30.www.ahrq.gov174000
31.www.netdoktor.de164000
32.www.docguide.com161000
33.www.jneurosci.org156000
34.www.emedicinehealth.com155000
35.www.orpha.net154000
36.www.pfizer.com136000
37.www.ninds.nih.gov135000
38.www.gsk.com135000
39.www.medizin-forum.de131000
40.www.e-carabin.net130000
41.www.thieme.de129000
42.www.socialsecurity.gov128000
43.www.valuemd.com125000
44.www.meddean.luc.edu123000
45.www.baua.de122000
46.www.guideline.gov117000
47.ajp.psychiatryonline.org110000
48.www.urmc.rochester.edu107000
49.www.vh.org106000
50.www.obgyn.net102000
Pages:  1  2  3  4  5  6  7  8  9  10  11  12 
 13  14  15  16 



Subscribe to RSS feed Subscribe to Feed Burner feed Add to Del.icio.us Add to Yahoo Add to Google Add to Reddit Add to Blink Add to Meneame Add to Fark Add to Newsvine

11. www.redcross.org

Rating: 343000 points*
*amount mentions of word 'www.redcross.org' on the other websites

www.redcross.org

American Red Cross - Preparing Communities for an Emergency and Keeping People Safe - Preparedness

Description: The American Red Cross helps prepare communities for emergencies and keep people safe every day thanks to caring people who support our work. Please support your local Red Cross.

Google

© 2005-2012 www.Top100Medicine.com
Not Sold on AVI BioPharma... Yet
VFC submits: Avi BioPharma, Inc. (AVII) is back on the radar of late, after releasing some positive news reports. On Monday morning Avi announced that it had landed a government contract with the U.S. Defense Threat Reduction Agency [DTRA] for the development of AVI-7100 (formerly identified as AVI-7367) as a medical countermeasure to a possible H1N1 virus pandemic outbreak. The contract could be worth up to $18 million. Just two months earlier, AVI had announced a similar agreement with the DTRA, with that contract being worth up to $4 million.Last week Avi also announced the positive results of a Phase 1b-2 clinical study for the company's drug treatment for Duchenne muscular dystrophy [DMD]. The study included 28 patients and was well tolerated by all, according to reports issued by the company.Complete Story »
seekingalpha.com
BioClinica Announces Second Quarter 2010 Financial Results (Business Wire)
NEWTOWN, Pa.----BioClinica™, Inc. , a global provider of clinical trial management services, today announced its financial results for the second quarter and six months ended June 30, 2010.
us.rd.yahoo.com
St. Jude Medical In Settlement Talks
St. Jude Medical is in settlement talks with the Justice Department regarding allegations the heart-device maker used medical studies to pay kickbacks and boost product usage.
online.wsj.com
Aetna CEO to Retire
Aetna Chairman and CEO Ronald A. Williams will step down as CEO next month, to be succeeded by President Mark T. Bertolini.
online.wsj.com
Abbott Laboratories Shares 'Marked Down' - Good Time to Buy?
Roger I. McNamara submits: Over several decades a fixture in both its Industry and the larger market/economy, Abbott Labs (ABT) has been tagged with a share price markdown in recent weeks. From the low-mid 50's of not long ago it now struggles to hold onto $47, slightly over 5% atop its 52 week closing low but fully 17% beneath its 52 week best. Similarly as with both 50 and 200 day moving averages north of 50, the stock is now offered at noticeable discounts. What has brought this about, and what should the savvy investor do about it?Among the pharmaceutical entrants ABT has stood aside with a fairly low --- either side of 60% --- revenue component derived from prescription compounds, the remainder faithfully arriving through nutritional supplements and an assortment of diagnostic and testing devices aimed at vascular and other health shortcomings. Put another way, its product slate is comparatively diversified. It has nonetheless been widely noticed and documented that the company's pipeline of life-supporting medications had become weak, or, as one commentator cleverly put it, ABT was not delivering enough "shots on goal" toward the Food and Drug Administration's net minders, who in the meantime have grown more demanding and selective before escorting a new member through Phase III clinical trials. In addition to bolstering research and development outlays, Abbott's management elected to mobilize its fortress balance sheet, sporting $12.68 net current assets per share at year end 2009, toward buying its way to a prosperous future.Complete Story »
seekingalpha.com